Biodegradable Polymer DES Versus Durable Polymer Everolimus-eluting Stents for Patients Undergoing PCI: A Meta-analysis - 04/06/14
Résumé |
Background |
Everolimus-eluting stents are associated with low risk of stent thrombosis and stent restenosis, and the new generation of stents with biodegradable polymer were designed to reduce that risk. However, the benefits have been variable.
Methods and results |
Four RCTs with a total of 8282 patients were included. Overall, BP-DES was not inferior to EES with equivalent risk of TVR (relative risk [RR], 1.07; 95% confidence interval [CI], 0.91–1.27; P=0.414; I2=0.0%) and ARC definite and/or probable ST (RR, 1.06; 95% CI, 0.66–1.70; P=0.810; I2=4.8%). Furthermore, there was no difference in all-cause mortality (RR, 1.06; 95% CI, 0.84–1.33; P=0.651; I2=0.0%), myocardial infarction (RR, 1.12; 95% CI, 0.88–1.44; P=0.360; I2=0.0%), and MACE (RR, 1.00; 95% CI, 0.87–1.15; P=0.975; I2=0.0%) between the two groups.
Conclusions |
The new generation of biodegradable polymer stents were not inferior to EES for equivalent risk of MACE and ST.
Le texte complet de cet article est disponible en PDF.Keywords : Biodegradable polymer, Everolimus-eluting stent, Target vessel revascularisation, Stent thrombosis, Percutaneous coronary intervention
Plan
Vol 23 - N° 6
P. 496-502 - juin 2014 Retour au numéro
Article précédent
- A Clip in time – Selecting Interventions for Severe Mitral Valve Regurgitation
- David W.M. Muller, Paul Jansz
- Diagnosis, Prognosis and Therapeutic Role of Circulating miRNAs in Cardiovascular Diseases
- Ali Sheikh Md Sayed, Ke Xia, Umme Salma, Tianlun Yang, Jun Peng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?